Concepedia

Diana Jakubiak

DJ

Statistics

Publications

5

Citations

690

H-Index

5

Active since

2013

Affiliations

Shanghai Zhangjiang Laboratory(Current)

Diana Jakubiak is an author at Shanghai Zhangjiang Laboratory specializing in pharmacology, molecular oncology, and pharmacy.

Publications per year

2013–2020

5

Publications

5

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP

Yi Zhou, Mingjian Fei, Gu Zhang et al. · Immunity · 2020 · 402 citations · Full text

Life Sciences, Immunology, Pharmacology +14

P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma

Christy C. Ong, Adrian M. Jubb, Diana Jakubiak et al. · JNCI Journal of the National Cancer Institute · 2013 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-p <i>K</i> <sub>a</sub> Polar Moiety

Chudi Ndubaku, James J. Crawford, Joy Drobnick et al. · ACS Medicinal Chemistry Letters · 2015 · 86 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window

Joachim Rudolph, Lesley Murray, Chudi Ndubaku et al. · Journal of Medicinal Chemistry · 2016 · 77 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

Elizabeth Blackwood, Jennifer Epler, Ivana Yen et al. · Molecular Cancer Therapeutics · 2013 · 37 citations · Full text

Life Sciences, Oncology, Pharmacology +17

1–5 of 5